New Approaches for the Treatment of Chronic GVHD

New Orleans, LA US
October 28, 2021

The purpose of this activity is to equip pharmacists and pharmacist technicians with the latest updates in the literature regarding newly approved therapies in the treatment of chronic GVHD. The updates in the management began with the approval of ibrutinib for use in refractory GVHD in 2016. In July and September of 2021, two more agents became available, belumosudil and ruxolitinib, respectively. By reviewing the literature based on which the therapies mentioned above were approved, this presentation will summarize the new important updates in chronic GVHD management to help providers better understand the newly approved agents' place in therapy. Having more options available for chronic GVHD may significantly decrease the burden of this complication for patients and improve their quality of life.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Characterize chronic graft-versus-host disease (GVHD) and describe its underlying pathophysiology
  2. Discuss the current approach in the treatment of chronic GVHD
  3. Evaluate the literature on the recently approved therapies in the treatment of chronic GVHD

Pharmacy technician learning objectives

  1. Recognize brand and generic names of new pharmacological agents used in treatment of chronic GVHD
  2. Review specific storage and dispensing information regarding oral agents used for chronic GVHD

Additional Information

AttachmentSize
PDF icon Helpful Tips for Users - Vizient CE System.pdf134.81 KB
File Information for CE Credit - New Approaches for the Treatment of Chronic GVHD.docx125 KB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
Course opens: 
10/28/2021
Course expires: 
12/12/2021
Event starts: 
10/28/2021 - 12:00pm CDT
Event ends: 
10/28/2021 - 1:00pm CDT
Add to calendar: 
Ochsner Medical Center
1514 Jefferson Highway
New Orleans, LA 70121
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose.
 
Planning committee members
Breanne Peyton Thomas, PharmD, BCOP
Clinical Oncology Pharmacist
Ochsner Medical Center
 
Bailey Wise, PharmD, BCPS
Clinical Pharmacist
Ochsner Medical Center
 
Course reviewer
Gretchen Brummel, PharmD, BCPS
Consulting Director, Pharmacy
Vizient, Inc.
 
Presenter
Iryna Mialik, PharmD
PGY2 Hematology/Oncology Pharmacy Practice Resident
Ochsner Medical Center
Joint Accreditation Statement:
 
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
____________________________________________
 
Designation Statement:
 
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-21-195-L01-P
Universal Activity Number: JA0006103-9999-21-195-L01-T

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
Please login or register to take this course.